Camp4 Therapeutics (CAMP) Asset Writedowns and Impairment (2025)

Camp4 Therapeutics (CAMP) reported Asset Writedowns and Impairment of -$6000.0 for Q4 2025, down 101.21% sequentially from $494000.0 in Q3 2025.

Camp4 Therapeutics (CAMP) Asset Writedowns and Impairment (2025) Analysis & Trends

Camp4 Therapeutics (CAMP) has 1 years of Asset Writedowns and Impairment data on file, last reported at -$6000.0 in Q4 2025.

For the quarter ending Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to -$6000.0; the trailing twelve-month figure through Dec 2025 stood at $488000.0 (changed N/A YoY), and the FY2025 full-year result was $494000.0, changed N/A from the prior year.
Asset Writedowns and Impairment retreated to -$6000.0 in Q4 2025, from $494000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $494000.0 in Q3 2025 to a low of -$6000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Camp4 Therapeutics	174.35 Mn	174.35 Mn	-

Download Data